他克莫司治疗儿童中重度特应性皮炎的临床研究

发布时间：2018-02-17 07:09

本文关键词： 他克莫司 T淋巴细胞特应性皮炎免疫　出处：《中国临床药理学杂志》2014年09期 　论文类型：期刊论文

【摘要】：目的评价他克莫司治疗儿童中重度特应性皮炎的临床疗效。方法 48例特应性皮炎患儿随机分为治疗组和对照组,各24例;另选择10例健康儿童为正常组。治疗组外用0.03%他克莫司涂抹,对照组外用凡士林涂抹,正常组不做任何处理。治疗3周后,比较各组患者临床疗效,测定血免疫球蛋白(IgE)、可溶性肿瘤坏死因子受体(sTNFR)、T淋巴细胞亚群和皮肤角质形成细胞热休克蛋白70(HSP70)的水平。结果治疗组总有效率为95.83%,明显高于对照组的43.47%。与对照组比较,治疗组的皮损症状积分、瘙痒症状积分和血IgE、sTNFR、T淋巴细胞亚群CD4+、CD4+/CD8+显著降低,皮肤角质形成细胞HSP70表达显著下调,差异均有统计学意义(P0.05)。治疗后,治疗组的sTNFR、T淋巴细胞亚群CD4+、CD4+/CD8+与正常组比较差异无统计学意义(P0.05)。结论他克莫司能有效缓解儿童中重度特应性皮炎皮损、瘙痒等症状。
[Abstract]:Objective to evaluate the clinical efficacy of tacrolimus in the treatment of moderate and severe atopic dermatitis in children. Methods 48 children with atopic dermatitis were randomly divided into treatment group and control group with 24 cases each. Another 10 healthy children were selected as normal group. The treatment group was treated with 0.03% tacrolimus, the control group was treated with vaseline, and the normal group was not treated. After 3 weeks of treatment, the clinical efficacy of each group was compared. The levels of serum immunoglobulin (IgE), soluble tumor necrosis factor receptor (TNFR) T lymphocyte subsets and keratinocyte heat shock protein 70 (HSP70) were measured. Results the total effective rate of the treatment group was 95.83, which was significantly higher than that of the control group (43.47%). In the treatment group, the scores of skin lesion symptom, pruritus symptom and blood IgE TNFR T lymphocyte subgroup, CD4 T lymphocyte subgroup, CD 4 / CD 8, and the expression of HSP70 in skin keratinocytes were significantly decreased (P 0.05). There was no significant difference in CD4 CD4 / CD8 between the treatment group and the normal group. Conclusion tacrolimus can relieve the symptoms of moderate and severe atopic dermatitis and pruritus in children.
【作者单位】：贵阳市妇幼保健院;
【分类号】：R758.2

【相似文献】